[ad_1]
Global Blood Therapeutics (NASDAQ: GBT) and Sol Gel Technologies (NASDAQ: SLGL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, badyst recommendations, risk, institutional ownership, earnings and profitability.
Insider and Institutional Ownership
99.0% of Global Blood Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Sol Gel Technologies shares are owned by institutional investors. 4.4% of Global Blood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe in stock is poised for long-term growth.
Earnings & Valuation
This table compares Global Blood Therapeutics and Sol Gel Technologies' gross revenue, earnings per share and valuation.
| Gross Revenue | Price / Sales Ratio | Net Income | Earnings Per Share | Price / Earnings Ratio | |
| Global Blood Therapeutics | N / A | N / A | – $ 117.02 million | ($ 2.76) | -14.45 |
| Sol Gel Technologies | $ 170,000.00 | 780.17 | – $ 31.56 million | ($ 5.02) | -1.40 |
Sol Gel Technologies has higher revenues than Global Blood Therapeutics. Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Sol Gel Technologies, indicating that it is currently the most affordable of the two stocks.
Profitability
This table compares Global Blood Therapeutics and Sol Gel Technologies' net margins, return on equity and return on badets.
| Net Margins | Return on Equity | Return on Assets | |
| Global Blood Therapeutics | N / A | -36.23% | -33.59% |
| Sol Gel Technologies | N / A | N / A | N / A |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Global Blood Therapeutics and Sol Gel Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Global Blood Therapeutics | 0 | 1 | 13 | 0 | 2.93 |
| Sol Gel Technologies | 0 | 0 | 4 | 0 | 3.00 |
Global Blood Therapeutics has a consensus of $ 83.14, suggesting a potential upside of 108.43%. Sol Gel Technologies has a consensus of $ 19.00, suggesting a potential upside of 171.04%. Given Sol Gel Technologies' stronger consensus rating and higher likely upside, badysts clearly believe Sol Gel Technologies is more favorable than Global Blood Therapeutics.
Summary
Sol Gel Technologies Global Blood Therapeutics on 6 of the 10 factors compared between the two stocks.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase II clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
About Sol Gel Technologies
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for the Global Blood Therapeutics Daily Click here to subscribe to the daily news of the latest news and badysts' ratings for Global Blood Therapeutics and related companies MarketBeat.com's FREE daily email newsletter.
Source link
